RxSight annual free cash flow
2020
2021
2022
2023
2024
2025
RxSight Free Cash Flow (FCF) History (RXST)
RxSight reported −$19.3M in free cash flow for fiscal 2025, an increase of $3.0M from the previous fiscal year, with a free cash flow margin of −14.38%.
View full RxSight company overviewRxSight free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$19.3M | $3.0M | — | −14.38% |
| 2024 | 2024-12-31 | −$22.4M | $24.0M | — | −16.00% |
| 2023 | 2023-12-31 | −$46.4M | $14.8M | — | −52.10% |
| 2022 | 2022-12-31 | −$61.2M | −$14.6M | — | −124.97% |
| 2021 | 2021-12-31 | −$46.6M | −$8.9M | — | −206.47% |
| 2020 | 2020-12-31 | −$37.7M | — | — | −257.13% |
RxSight quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$11.5M | −$5.6M | — | −42.19% |
| Q1 2026 | 2026-03-31 | −$11.7M | −$2.2M | — | −37.71% |
| Q4 2025 | 2025-12-31 | −$2.3M | $2.9M | — | −6.91% |
| Q3 2025 | 2025-09-30 | −$1.8M | −$1.3M | — | −5.83% |
| Q2 2025 | 2025-06-30 | −$5.9M | −$363,000 | — | −17.58% |
| Q1 2025 | 2025-03-31 | −$9.4M | $1.9M | — | −24.82% |
| Q4 2024 | 2024-12-31 | −$5.1M | $4.8M | — | −12.70% |
| Q3 2024 | 2024-09-30 | −$453,000 | $8.2M | — | −1.28% |
| Q2 2024 | 2024-06-30 | −$5.5M | $3.8M | — | −15.91% |
| Q1 2024 | 2024-03-31 | −$11.3M | $7.2M | — | −38.21% |
| Q4 2023 | 2023-12-31 | −$9.9M | $4.3M | — | −34.61% |
| Q3 2023 | 2023-09-30 | −$8.6M | $7.1M | — | −38.90% |
| Q2 2023 | 2023-06-30 | −$9.4M | $6.5M | — | −45.02% |
| Q1 2023 | 2023-03-31 | −$18.5M | −$3.2M | — | −105.84% |
| Q4 2022 | 2022-12-31 | −$14.2M | −$5.1M | — | −88.36% |
| Q3 2022 | 2022-09-30 | −$15.8M | −$1.8M | — | −124.99% |
| Q2 2022 | 2022-06-30 | −$15.9M | −$3.1M | — | −140.00% |
| Q1 2022 | 2022-03-31 | −$15.4M | −$4.6M | — | −171.72% |
| Q4 2021 | 2021-12-31 | −$9.1M | −$1.5M | — | −107.84% |
| Q3 2021 | 2021-09-30 | −$14.0M | — | — | −242.12% |
| Q2 2021 | 2021-06-30 | −$12.8M | — | — | −261.43% |
| Q1 2021 | 2021-03-31 | −$10.8M | — | — | −308.55% |
| Q3 2020 | 2020-09-30 | −$7.6M | — | — | −181.08% |
RxSight free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$37.7M to −$19.3M, a net increase of $18.4M. RxSight's latest reported quarter, Q2 2026, generated −$11.5M in free cash flow, a decrease of $5.6M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review RxSight filings at SEC.gov ↗